Information Disclosure Statements

Prior art cited in related applications

References cited in counterpart foreign applications (EPO/JPO/CNIPA search reports and office actions), in parent/sibling US applications, and in related litigation. Foreign search reports are the most common trigger for supplemental IDS filings.

References found in your own pre-filing search

If a patentability search was conducted, material references it located must be cited. There is no duty to perform a search — but there is an absolute duty to disclose what you actually know.

The applicant's own activities and publications

The inventors' prior papers, conference presentations, product launches, public demos, and on-sale activity that predate the filing — your own disclosures can be § 102 art against you, and they are squarely material.

Art identified by third parties

References pointed out in licensing discussions, demand letters, investor diligence, or litigation involving related patents. Once anyone under the duty learns of material art, the clock starts.

Material information beyond patents and papers

Materiality is not limited to documents: inconsistent statements made to other patent offices or courts, test data contradicting arguments made to the examiner, and known public uses can all be material information under § 1.56.

What is an Information Disclosure Statement (IDS)?

An Information Disclosure Statement is the formal mechanism by which a patent applicant discloses known prior art and other material information to the USPTO during prosecution. It implements the duty of disclosure (duty of candor and good faith) codified at 37 C.F.R. § 1.56: each individual associated with the filing and prosecution of a patent application has a duty to disclose to the Office all information known to that individual to be material to patentability. Mechanics: the IDS consists of a listing of references (form PTO/SB/08, listing US patents and published applications, foreign patent documents, and non-patent literature) plus copies of foreign-language documents and non-patent literature (copies of US patents and published applications are not required), with a concise explanation of relevance required for non-English documents. The examiner considers the cited references and initials each one; considered references are printed on the face of the issued patent. Key clarifications: (1) Filing an IDS is not an admission that the cited references are prior art or that they are material — the regulation says so expressly (§ 1.97(h)); applicants routinely over-disclose out of caution. (2) There is no duty to search — the duty attaches only to information actually known to individuals covered by the duty. (3) The duty is continuing: it runs until the patent issues, so art learned mid-prosecution (typically from foreign counterpart search reports) must be disclosed through supplemental IDS filings under the timing rules of § 1.97. (4) Strategic upside of disclosure: art that the examiner considered and initialed is far harder to use against the patent later — challengers prefer art the Office never saw.

Who owes the duty of disclosure to the USPTO?

Under 37 C.F.R. § 1.56(c), the duty of disclosure applies to: (1) each named inventor; (2) each attorney or agent who prepares or prosecutes the application; and (3) every other person who is substantively involved in the preparation or prosecution of the application AND who is associated with the inventor, the applicant, an assignee, or anyone to whom there is an obligation to assign. What 'substantively involved' means in practice: in-house counsel managing the application, engineers or scientists who contribute technical content to the specification or responses, R&D managers who review claims — but not administrative staff, paralegals performing clerical work, or company executives with no substantive role in the application. Important boundaries: (1) The duty is individual, not corporate — but a company cannot launder knowledge by walling off the prosecuting attorney from employees who know the art; courts have found inequitable conduct where individuals under the duty deliberately withheld art from their own patent counsel. (2) Knowledge is not imputed across the organization automatically — the issue is what the covered individuals actually knew. (3) The duty covers information material to patentability of the pending claims — as claims are amended, materiality can change; art irrelevant to original claims can become material to amended ones. (4) The duty ends when the patent issues (for that patent), but reattaches in continuations, reissues, and reexaminations. Practical compliance: prosecution counsel typically circulate reminders to inventors at filing and during prosecution, and companies maintain procedures to route foreign search reports and litigation references to the prosecuting attorney for IDS submission.

What does 'material to patentability' mean for IDS purposes?

Two different standards coexist, and careful practitioners disclose to the broader one. (1) The USPTO rule standard — 37 C.F.R. § 1.56(b): information is material if it is not cumulative to information already of record and (a) it establishes, alone or in combination, a prima facie case of unpatentability of any claim, or (b) it refutes, or is inconsistent with, a position the applicant takes in arguing patentability or opposing an Office rejection. (2) The inequitable conduct standard — Therasense, Inc. v. Becton, Dickinson & Co. (Fed. Cir. 2011, en banc): for withheld information to support an inequitable conduct finding in litigation, it must meet 'but-for materiality' — the Office would not have allowed a claim had it been aware of the reference (judged under the Office's preponderance standard with broadest reasonable claim interpretation). Therasense also requires clear and convincing proof of specific intent to deceive — the single most reasonable inference from the evidence must be deliberate withholding to deceive the Office; gross negligence and 'should have known' are not enough. An exception exists for affirmative egregious misconduct (e.g., filing fabricated test data), which is material per se. Practical takeaways: (a) disclose to the § 1.56 standard, which is broader than but-for — the cost of citing a borderline reference is trivial; the cost of a later inequitable conduct fight is enormous; (b) cumulative art need not be cited, but judging cumulativeness is risky — when in doubt, cite; (c) inconsistent statements to other patent offices about the same art are a recurring inequitable conduct fact pattern — keep positions consistent across jurisdictions.

What happens if material prior art is withheld from the USPTO?

The consequence is inequitable conduct — a judge-made doctrine rendering the ENTIRE patent unenforceable, not just the claims the withheld art would have defeated. The modern standard comes from Therasense, Inc. v. Becton, Dickinson & Co. (Fed. Cir. 2011, en banc), which deliberately tightened the doctrine after decades of it being pleaded 'in nearly every patent suit' as a 'plague.' The accused infringer must prove, by clear and convincing evidence: (1) But-for materiality — the USPTO would not have allowed at least one claim if it had known of the withheld information (evaluated under the Office's preponderance-of-evidence standard and broadest reasonable interpretation); and (2) Specific intent to deceive — knowledge of the reference, knowledge of its materiality, and a deliberate decision to withhold it; intent must be 'the single most reasonable inference' from the evidence. Negligence, even gross negligence, is insufficient, and intent cannot be inferred from materiality alone. The exception: affirmative egregious misconduct — like submitting fabricated declarations or false data — is material per se without but-for analysis. Consequences when found: the entire patent is unenforceable forever (not invalid — unenforceable, which also cannot be fixed by reissue); unenforceability can extend to related patents in the family infected by the same conduct; the case may be deemed exceptional under 35 U.S.C. § 285, supporting attorney fee awards; and the attorney involved faces OED discipline. Post-AIA remediation: supplemental examination (35 U.S.C. § 257) lets a patent owner ask the Office to consider, reconsider, or correct information after grant — and information considered in supplemental examination generally cannot later support an inequitable conduct claim, IF the process completes before litigation or certain deadlines. It is the designed inoculation route for skeletons discovered in the portfolio.

When can I file an IDS during prosecution and what does timing cost?

37 C.F.R. § 1.97 defines escalating windows: (1) Window 1 — within three months of the US filing date (or national stage entry), or before the first Office Action on the merits, whichever is later: the IDS is considered with no fee and no certification. Also applies within three months of the first citation in an RCE. (2) Window 2 — after the first Office Action but before a final Office Action or notice of allowance: the IDS requires either the § 1.97(e) certification or the IDS fee. The certification states that either (A) each item was first cited in a communication from a foreign patent office in a counterpart application no more than three months before the IDS, or (B) no item was known to any individual under the duty of disclosure more than three months before the IDS. This is the standard route for foreign search report citations — docket the foreign citation date and file within three months to avoid the fee. (3) Window 3 — after final action or allowance but before payment of the issue fee: BOTH the certification AND the fee are required. If you cannot truthfully certify (e.g., the reference was known for years), the IDS cannot be entered — the options become filing an RCE (reopening prosecution) or, after allowance, the QPIDS program. (4) After the issue fee: no IDS can be entered. QPIDS (Quick Path IDS) allows consideration after issue fee payment without a full RCE — the examiner reviews the reference; if no new ground of rejection is found, the patent proceeds to grant. Otherwise: petition to withdraw from issue plus RCE. After grant, the routes are reissue, ex parte reexamination, or supplemental examination. Practice points: batch references sensibly but never sit on a known material reference across windows — delay itself becomes evidence in a later intent fight; and remember the duty continues until issue, so late-arriving foreign citations on allowed cases are a routine (and routinely mishandled) trap.